NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 40.01 P/S
- 19.17 P/B
- -0.31 EPS
- -2,078.99% Cash ROIC
- 1.62 Cash Ratio
- 0 / 0% Dividend
- 414,462.00 Avg. Vol.
- 49.63M Shares
- 42.78M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Smarter Analyst - May 15, 2015
Benzinga - May 22, 2015
StreetInsider.com - May 22, 2015
The Wall Street Transcript - Mar 9, 2015
Yahoo Finance UK - May 1, 2015
Seeking Alpha - Apr 21, 2015
Business Wire (press release) - May 14, 2015
StreetInsider.com - May 6, 2015
Business Wire (press release) - Apr 14, 2015
Benzinga - Apr 30, 2015
Novabay Pharmaceuticals Coverage Initiated at Maxim Group (NBY) - Mideast Time